Free Trial
NASDAQ:STRO

Sutro Biopharma Q4 2023 Earnings Report

Sutro Biopharma logo
$0.95 -0.10 (-9.52%)
As of 02:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sutro Biopharma EPS Results

Actual EPS
$0.42
Consensus EPS
-$0.82
Beat/Miss
Beat by +$1.24
One Year Ago EPS
N/A

Sutro Biopharma Revenue Results

Actual Revenue
$113.72 million
Expected Revenue
$12.16 million
Beat/Miss
Beat by +$101.56 million
YoY Revenue Growth
N/A

Sutro Biopharma Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 25, 2024
Conference Call Time
5:30PM ET

Upcoming Earnings

Sutro Biopharma's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sutro Biopharma Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
See More Sutro Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email.

About Sutro Biopharma

Sutro Biopharma (NASDAQ:STRO) operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

View Sutro Biopharma Profile

More Earnings Resources from MarketBeat